4//SEC Filing
HENNEMAN JOHN B III 4
Accession 0001104659-24-034671
CIK 0001781983other
Filed
Mar 13, 8:00 PM ET
Accepted
Mar 14, 8:52 PM ET
Size
10.7 KB
Accession
0001104659-24-034671
Insider Transaction Report
Form 4
HENNEMAN JOHN B III
Director
Transactions
- Purchase
Common Stock
2024-03-13$7.29/sh+6,860$50,009→ 8,139 total - Purchase
Tranche A Warrant
2024-03-13+3,430→ 3,430 totalFrom: 2024-03-13→ Common Stock (3,430 underlying) - Purchase
Tranche B Warrant
2024-03-13+3,430→ 3,430 totalFrom: 2024-03-13→ Common Stock (3,430 underlying)
Footnotes (6)
- [F1]The exercise price of the Tranche A Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share.
- [F2]Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.
- [F3]The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.
- [F4]The exercise price of the Tranche B Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share.
- [F5]Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.
- [F6]The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.
Documents
Issuer
Aprea Therapeutics, Inc.
CIK 0001781983
Entity typeother
Related Parties
1- filerCIK 0001187572
Filing Metadata
- Form type
- 4
- Filed
- Mar 13, 8:00 PM ET
- Accepted
- Mar 14, 8:52 PM ET
- Size
- 10.7 KB